Millie
your market intelligence analyst
Search Results
658 results
Your search is now limited to «Company News in Cardiovascular Diseases» expert search.
NASDAQ 10/22/2019 09:06
However, as competition in the MS market intensifies, Biogen is trying to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.
More from NASDAQ:
PMLiVE 10/22/2019 04:26
Boehringer and Lilly are testing Jardiance in both HFrEF and HFpEF with two trials – EMPEROR-Reduced and EMPEROR-Preserved – also due to generate results in 2020.
More from PMLiVE:
FDA approves AstraZeneca’s Farxiga to treat heart failure in diabetic.
More from Pharmaceutical Business Review:
Benzinga 10/21/2019 12:42
Farxiga now offers the opportunity for physicians to act sooner and reduce the risk of hospitalization for heart failure," said Ruud Dobber, executive vice president of AstraZeneca's biopharma unit, said in a statement.
More from Benzinga:
News-Medical.net 10/21/2019 11:09
Ratan Bhat, head of strategy and external innovation within Cardiovascular, Renal and Metabolism at AstraZeneca adds: "Working with SciLifeLab enables us to access novel technology and science.
More from News-Medical.net:
FiercePharmaManufacturing 10/21/2019 10:54
The FDA’s expedited review will cover Farxiga’s pursuit of indications in both HFrEF and heart failure patients with a preserved ejection fraction, AstraZeneca said at the time.
More from FiercePharmaManufacturing:
ENDPOINTS 10/21/2019 08:55
In September, AstraZeneca unveiled data from the DAPA-HF trial, which showed the drug cut the risk of CV death or the worsening of heart failure in patients with heart disease.
More from ENDPOINTS:
Wearable Technologies 10/21/2019 06:07
Wearable device maker Fitbit and pharmaceutical giants Bristol-Myers Squibb and Pfizer have signed a multiyear partnership to speed up the detection and diagnosis of atrial fibrillation (AFib) to reduce the risk of life-threatening events such as stroke.
More from Wearable Technologies:
Pharmafile 10/21/2019 04:40
AstraZeneca have announced that the US FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure in adults with type-2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors ...
More from Pharmafile:
FeedNavigator (EU) 10/21/2019 03:59
FDA approves AstraZeneca diabetes drug for treating heart failure risk.
More from FeedNavigator (EU):
ETHealthWorld (India) 10/21/2019 03:07
The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval by the European authorities in August.
More from ETHealthWorld (India):
Reuters.com 10/21/2019 02:35
AstraZeneca Plc said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.
More from Reuters.com:
Channel NewsAsia (Singapore) 10/21/2019 02:35
US FDA approves AstraZeneca's diabetes drug for treating heart failure risk.
More from Channel NewsAsia (Singapore):
STAT 10/18/2019 09:29
Takeda recalled the product after learning rubber particles may clog needles in multi-dose cartridges that deliver the solution.
More from STAT:
Drug Store News 10/18/2019 08:00
With flu season rapidly approaching, we can now offer Xofluza as the first and only FDA approved treatment option indicated specifically for those at high risk of flu complications,” said Levi Garraway, Roche’s chief medical officer and head of global product development.
More from Drug Store News:
PharmaTimes 10/18/2019 06:58
The pre-existing Bristol-Myers Squibb and Pfizer Alliance is committed to driving education and awareness about atrial fibrillation and venous thromboembolism.
More from PharmaTimes:
eHealthNews.EU Portal (EU) 10/18/2019 06:00
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier ...
More from eHealthNews.EU Portal (EU):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications